Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019
PXL065 observed to have a favorable safety, tolerability and pharmacokinetic (PK) profile in the Phase 1a trial PXL065 intends to utilize the 505(b)(2) regulatory pathway, which offers the opportunity for a…
Read this Press Release: Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019Poxel Announces Positive Update Following FDA Meeting for PXL065 for Treatment of NASH
FDA feedback supports plan to advance PXL065 using the 505(b)(2) regulatory pathway for NASH 505(b)(2) process offers opportunity for a streamlined and efficient development plan Poxel provides update on PXL065…
Read this Press Release: Poxel Announces Positive Update Following FDA Meeting for PXL065 for Treatment of NASHPoxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting® 2019
LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting® 2019
Upcoming Events
Jefferies Global Healthcare Conference
World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease
